drugset / Trial / NCT01281514
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboplatin and PLD together with everolimus may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with carboplatin and PLD in treating patients with relapsed ovarian epithelial, fallopian tube, or peritoneal cavity cancer
Timeline
- Start
- 2010-12-14
- Primary completion
- 2018-01-08
- Completion
- 2018-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | pegylated liposomal doxorubicin hydrochloride | Unknown | — | Intravenous |